Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - fluorouracil, quantity: 40 mg/g - cream - excipient ingredients: stearoyl macrogolglycerides; butylated hydroxytoluene; cetyl alcohol; citric acid; glycerol; isopropyl myristate; methyl hydroxybenzoate; propyl hydroxybenzoate; purified water; arachis oil; sodium hydroxide; stearic acid; stearyl alcohol; methyl gluceth-10 - tolak 4% once daily is indicated for the topical treatment of actinic keratosis (ak) of the face, ears, and/or scalp in adults.

Israel - Inggeris - Ministry of Health

padagis israel pharmaceuticals ltd, israel - clotrimazole - cream - clotrimazole 1 %w/w - clotrimazole - clotrimazole - for the treatment of fungal infections of the skin and mucosa caused by dermatophytes, yeasts, molds and other fungi such as malassezia furfur, as well as skin infections caused by corynebacterium minutissimum.indicated also for candida vulvitis and candida balanitis.

Israel - Inggeris - Ministry of Health

bayer israel ltd - clotrimazole - cream - clotrimazole 1 %w/w - clotrimazole - clotrimazole - for the treatment of fungal infections of the skin and mucosa caused by dermatophytes, yeasts, moulds and other fungi such as malassezia furfur as well as skin infections caused by corynebacterium minutissimum. indicated also for candida vulvitis and candida balanitis.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

haleon australia pty ltd - hydrocortisone, quantity: 1 % w/w; clotrimazole, quantity: 1 % w/w - cream - excipient ingredients: cetomacrogol 1000; purified water; lactic acid; chlorocresol; cetostearyl alcohol; white soft paraffin; sodium hydroxide; glycerol; propylene glycol; light liquid paraffin - for dermatophyte and yeast infections of the skin when inflammation is prominent. this includes conditions such as fungal infected dermatitis, intertrigo and candida nappy rash.

Israel - Inggeris - Ministry of Health

megapharm ltd - fluorouracil - cream - fluorouracil 50 mg / 1 g - pyrimidine analogues - antineoplastic agent to treat actinic keratosis multiple and superfacial basel cell carcinoma.

Malta - Inggeris - Malta Medicines Authority

mylan ire healthcare limited unit 35/36, grange parade, baldoyle industrial estate, dublin 13, ireland - fluorouracil - cream - fluorouracil 5 % (w/w) - antineoplastic agents

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

lacorium health international pty ltd - tolnaftate, quantity: 10 mg/g - cream - excipient ingredients: menthol; purified water; glycerol; monobasic sodium phosphate; cetyl alcohol; aloe vera; lavender oil; propylene glycol; urea; dl-alpha-tocopheryl acetate; polysorbate 60; cetostearyl alcohol; benzalkonium chloride; ceteareth-20; white soft paraffin; light liquid paraffin - for the treatment of athlete's foot and ringworm. antifungal action relieves itchy, burning and irritated feet. provides soothing, cooling effect for irritated, painful feet. provides rapid, effective relief of itchy, cracked skin associated with athlete's foot. protects feet from various micro-organisms, bacteria and germs. moisturizes and hydrates dry,cracked, flaky skin.

Israel - Inggeris - Ministry of Health

padagis israel pharmaceuticals ltd, israel - clotrimazole; hydrocortisone acetate - cream - clotrimazole 1 %; hydrocortisone acetate 1 % - hydrocortisone - hydrocortisone - skin inflammation involving fungal infection

Israel - Inggeris - Ministry of Health

glaxo smith kline (israel) ltd - permethrin - cream - permethrin 5 %w/w - permethrin - permethrin - is indicated for the treatment of scabies.

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

ge healthcare inc. - human albumin microspheres (unii: t8c6w1n6nw) (human albumin microspheres - unii:t8c6w1n6nw), perflutren (unii: ck0n3wh0sr) (perflutren - unii:ck0n3wh0sr) - human albumin microspheres 10 mg in 1 ml - optison is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricle and to improve the delineation of the left ventricular endocardial borders. do not administer optison to patients with known or suspected hypersensitivity to perflutren or albumin [see warnings and precautions (5.5)] . risk summary there are no data with optison use in pregnant women to inform any drug-associated risks. no adverse developmental outcomes were observed in animal reproduction studies with intravenous administration of optison to pregnant rats and rabbits during organogenesis at doses up to at least 5 and 10 times the recommended human dose based on body surface area (see data ). in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. data animal data optison was administered intravenously to rats at doses of 0.25, 5 and 10 ml/kg/day (approximately 0.2, 5 and 10 times the recommended maximum human dose of 8.7 ml, respectively, based on body surface area) and to rabbits at 0.25, 2.5 and 5 ml/kg/day (approximately 0.5, 5 and 10 times the recommended maximum human dose, respectively, based on body surface area) during organogenesis. no significant findings attributable solely to a direct effect on the fetus were detected in the studies. there are no data on the presence of perflutren protein-type a microspheres in human milk, the effects on the breastfed infant, or the effects on milk production. the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for optison and any potential adverse effects on the breastfed infant from optison or from the underlying maternal condition. safety and effectiveness in pediatric patients have not been established. of the total number of subjects in a clinical study of optison, 35% were 65 and over, while 14% were 75 and over. no overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.